The introduction of selective tyrosine-kinase inhibitors (TKIs) for the treatment of chronic
myeloid leukaemia has changed patient outcome and, consequently, management of this …

Updated findings from a randomised comparison of imatinib versus previous standard
treatment in the treatment of newly diagnosed chronic myeloid leukaemia suggest that this …

Despite the remarkable results achieved with imatinib for the treatment of chronic myeloid
leukaemia, the emergence of resistance to this tyrosine kinase inhibitor has become a …

Imatinib is a molecularly targeted therapy that inhibits the oncogenic fusion protein BCR-
ABL, the tyrosine kinase involved in the pathogenesis of chronic myelogenous leukemia …

Targeted therapy in the form of selective tyrosine kinase inhibitors (TKI) has transformed the
approach to management of chronic myeloid leukemia (CML) and dramatically improved …

Although only 5000 new cases of chronic myeloid leukemia (CML) were seen in the United
States in 2009, this neoplasm continues to make scientific headlines year-after-year …

Selective inhibition of the BCR-ABL tyrosine kinase by imatinib has substantially changed
the therapy of chronic myelogenous leukemia (CML). Despite high rates of hematologic and …

Imatinib is, at present, the first-choice treatment for patients with chronic myeloid leukaemia
in chronic phase. Despite the impressive rate of complete haematological response and …

Mechanisms of resistance to the tyrosine kinase inhibitor (TKI) imatinib had been modeled in
vitro even prior to the first reports of clinical resistance in patients with chronic myeloid …

Since its approval in 2001 for frontline management of chronic myelogenous leukemia
(CML), imatinib has proven to be very effective in achieving high remission rates and …